Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
COYA
COYA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
COYA News
Coya Therapeutics Secures $11.1 Million in Private Placement
Jan 30 2026
seekingalpha
Coya Therapeutics Secures $11.1 Million in Private Placement
Jan 30 2026
Yahoo Finance
Coya Therapeutics Receives FDA IND Approval for COYA 302 to Treat Frontotemporal Dementia
Jan 05 2026
Newsfilter
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics with $15 Price Target Intact
Nov 12 2025
Benzinga
Coya Therapeutics Reveals Pricing for Increased $20 Million Public Offering of Common Stock
Oct 24 2025
Newsfilter
Coya Therapeutics Declines Following $20M Stock Offering Announcement
Oct 24 2025
SeekingAlpha
Coya Therapeutics Unveils Plans for Public Offering of Common Stock
Oct 23 2025
Newsfilter
David Einhorn's Greenlight Chooses This Small Biotech Over AI Hype
Oct 22 2025
MarketWatch
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia
Sep 29 2025
PRnewswire
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis
Sep 22 2025
PRnewswire
D. Boral Capital Reiterates Buy Rating for Coya Therapeutics with $18 Price Target Intact
Sep 17 2025
Benzinga
EXCLUSIVE: Coya Therapeutics' Investigational GLP-1 Combination Therapy Shows Promise for Alzheimer's Disease
Sep 16 2025
Benzinga
Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model
Sep 16 2025
PRnewswire
Biotech Stocks Soar in After-Hours Trading: CAPR and TMDX Top the List Following Trial News and Earnings Boost
Sep 09 2025
NASDAQ.COM
Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial
Sep 04 2025
PRnewswire
PRISM MarketView Presents Exclusive Interview with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases with Treg Therapies
Sep 03 2025
Newsfilter
Show More News
